Ivabradin Teva

Ivabradine, the active ingredient in Ivabradin Teva, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in suitable patients.

GNH USA supplies Ivabradin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive documentation, temperature‑controlled logistics where required, and responsive technical support.

Ivabradine is used to manage conditions related to myocardial oxygen demand and heart‑rate regulation.

Chronic stable angina pectoris: improves exercise tolerance by lowering heart rate. Heart failure with reduced ejection fraction: reduces hospitalization risk through heart‑rate reduction. Patients intolerant to beta‑blockers: offers an alternative mechanism for heart‑rate control.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo: especially on standing. - Fatigue: general feeling of tiredness. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Symptomatic hypotension leading to fainting. - Visual loss or persistent retinal changes. - Myocardial infarction in high‑risk patients.

Ivabradine should be prescribed only after confirming a resting heart rate above 50 bpm and evaluating for contraindications.

Monitor heart rate: ensure it remains within therapeutic range during therapy. Assess for atrial fibrillation: discontinue if new‑onset AF occurs. Avoid use in severe hepatic impairment: dose adjustment may be required. Caution in patients with hypotension: monitor blood pressure regularly. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with drugs that affect cardiac conduction or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels. - Concomitant use with other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Certain anti‑arrhythmic drugs (e.g., amiodarone): can potentiate bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - Drugs that prolong QT interval: monitor ECG for additive effects. - Rifampicin (CYP3A4 inducer): may reduce ivabradine exposure, affecting efficacy.